CommunityNews & Policy

Eli Lilly phase 3 Eloralintide trial is enrolling for Plateau Busting research

23 replies15 peopleApr 23, 2026☆ Follow
Summary

What details exist on the Eli Lilly Eloralintide phase 3 trial for people stalled on GLP-1s and how does it compare to cagrilintide in the grey market context?

The trial is open for participants on stable tirzepatide or semaglutide doses who have not lost more than 5% body weight in 90 days, providing the study drug or placebo plus six months of the current GLP-1 at no cost along with compensation for visits. Participants note that eloralintide is more amylin-selective than cagrilintide and produced roughly double the weight loss in earlier data with fewer GI effects. Grey market discussion centers on upcoming availability, testing challenges, and whether stacking will exceed current options.

What this discussion establishesWhere people disagree

Whether the 5% weight stability criterion is strict enough to produce meaningful plateau-busting results

Still open

How eloralintide will perform in combination with retatrutide and whether grey market versions will match trial material

Nothing here is advice.

23 replies · 15 people
BlueSparrow70archiveopening postApr 23

I came across details on a late-stage trial for this medication and saw it's currently recruiting participants. It targets those stuck after progress on their existing weekly treatments has stopped. The sponsor supplies the new compound or an inactive version without charge to check if it restarts the process. I'm not sure if the base medication gets covered or if any support payment is offered instead. The whole thing runs for roughly a year and a half and involves about two dozen in-person appointments. Eligibility calls for a certain body mass level or an added health condition along with steady use of the prior therapy and no meaningful scale changes over the prior three months plus a record of past diet or activity attempts that didn't work. Recent shifts in dosing or bigger weight moves would rule someone out along with any big medical procedures or use of unofficial versions that lack pharmacy proof. This research matters so only reach out to a local site if full commitment is realistic.

CopperSignal27archiveApr 23

I'm glad this is moving forward. The existing approved versions work well and the new one will too when it's cleared yet for those with higher levels of excess weight they may fall short. I hope the way they define a plateau isn't too lenient since a small shift in a short period adds up to substantial over longer time which isn't really stuck so maybe they'll use tighter standards to make findings more useful. Pairing this latest with the upcoming option might be the top unofficial choice for shedding pounds once it's easier to get. Data from mixing the current leader with the new addition could preview how well it works together. It will take some time to see outcomes but there won't be research on combining the others because of who owns them so it should be noteworthy.

GreyThistle88archiveApr 23
↳ replying to @BlueSparrow70 (opening post)

This may be an issue for many of us. I have a prescription for 12 mg tirzepatide but have not used it since my first compounding purchase last year. My doctor adjusts the prescription based on what I report. They might accept purchase history as proof of being on reta since last August. I am not stalled yet so I probably would not qualify anyway. That is fine because I would not want to end up in the placebo group.

SteadyCinder62archiveApr 23

Novo did Cagrilintide while this is Lilly. It looks promising for the plateau busting market. Cagrilintide activates amylin plus calcitonin receptors. Eloralintide was designed to be more selective for amylin receptors with less calcitonin activity.

QuietAnchor73archiveApr 23

How long until it hits the grey market?

GreenBeacon89archiveApr 27

This is interesting. They are not recruiting in Australia yet but I signed up on the company website to check eligibility. I still have a script for Mounjaro even though I am using grey tirz. I wonder if they will exclude people on reta.

SteadySignal83archiveApr 27

What sets this apart from the other one?

KeenPebble33archiveApr 28
↳ replying to @SteadySignal83

They turn out to be rather unlike each other in their makeup. The first one doesn't zero in solely on those amylin receptors numbered one and three. It also hits the calcitonin ones. By contrast the second sticks exclusively to the amylin ones. What stands out more is how the initial option leads to only around ten percent drop in weight while the other achieves double that after nearly twelve months. This creates a notable gap in their effects on body mass reduction.

CopperHarbour29archiveApr 29

During a conversation the head of the firm mentioned expecting this one to outperform the rival option since trial data shows roughly a fifth less body mass along with barely any stomach issues.

KeenPebble33archiveApr 29
↳ replying to @CopperHarbour29

Imagine what stacking it with reta or even tirz could do. Lilly is way ahead of Novo.

CopperHarbour29archiveApr 29
↳ replying to @KeenPebble33

They are testing stacking it with tirz. It could deliver reta level results with fewer side effects. He seemed confident that one of the two would be a blockbuster.

SharpCompass32archiveApr 29
↳ replying to @CopperHarbour29

I am currently in the screening process. They are stacking eloralintide or placebo with either semaglutide or tirzepatide. If you qualify you receive six months of whichever GLP-1 you are already on for free plus either eloralintide or placebo.

SharpCompass32archiveApr 29

I came across the survey link through a social media advertisement from a medication company. It gathered basic details about my health background, any existing issues, the amount of my current injection, and how much weight had come off over the past few months. Following that, they did a phone interview, and I gave permission for them to reach my physician for the files. Two in-person visits have been set up for bloodwork and an exam. Proof of the prescription hasn't been requested so far. My doctor wrote it, so that shows up in the records, even though I stopped getting refills months ago. The tracking tool indicates more than five percent lost over the last quarter. I'm not certain what figure appears in the doctor's notes, which could turn out fine or not. The next appointment in a couple weeks will be the last check before deciding on study acceptance.

KeenPebble33archiveApr 29
↳ replying to @SharpCompass32

That is a super interesting study. There is synergy between cagri and sema so I will be interested in the synergy of elora with tirz since both are more efficacious than cagri/sema. I hope it reaches the 30% range over a year. The six month data should be well above even reta.

WryTimber20archiveMay 17

Breaking through a stall sounds fantastic. I should probably examine that research. Receiving the medication without charge for half a year along with something new seems appealing. Even ending up with just the dummy version makes it worthwhile.

SharpCompass32archiveMay 17
↳ replying to @WryTimber20

You also get paid for all the visits. They told me it would total around four thousand dollars if I attend all twenty one appointments.

WryTimber20archiveMay 17
↳ replying to @SharpCompass32

The one place in my state is fifteen minutes from me. I will have to call on Monday.

PatientAlder89archiveMay 18

Yeah once the initial buzz fades away it'll end up costing way less!!

AmberKettle85archiveMay 18
↳ replying to @WryTimber20

If you are taking any investigational products they might not let you in the study. Worth asking what the inclusion and exclusion criteria are.

AmberKettle85archiveMay 18

I'm curious about how this stacks up against the standard glp versions by themselves, and versus that other peptide, particularly because of possible clumping problems if the acidity level isn't low enough. It looks like too much trouble, especially since the new one has really good early data. Can't wait to find out about the next trials because I need stronger hunger blocking effects from this compound.

PatientSignal60archiveMay 19
↳ replying to @GreenBeacon89

Not sure how to get involved if the information states participation is unavailable at present. Is there a way someone can provide the site location?

QuietSignal61archiveMay 19
↳ replying to @AmberKettle85

From my perspective this doesn't seem like a concern at all. The exception would be if injected straight into the bloodstream. It seems to me that one option could turn out stronger in results compared with the alternative. Certain individuals report no benefits from the alternative or mention it leads to significant exhaustion.

GreenBeacon89archiveMay 19
↳ replying to @PatientSignal60

I spotted a page where you can check into studies run by that firm. Folks who sign up help bring fresh treatments to life. You can look around for ones happening nearby through their main setup. Even though it's focused on one country there are ways to note your interest from other places too. Getting in isn't promised but trying seems reasonable. Tracking down the nearest location and reaching out for the latest info is another option.

GreyThistle88archiveMay 19

Thought it might be useful to include this discussion. It goes into the problems with analyzing the product and explains that even if tests show purity or certain specs that doesn't confirm it's worthwhile. I couldn't follow most of the details so I have no opinion on whether the claims hold up. It may end up being unimportant similar to the fibers mentioned with the other item. The suggestion is to observe what happens next prior to making a purchase. Thanks to those who went ahead and bought it anyway please update us on results. My budget doesn't allow it currently but I'm keen on seeing it become available in the unregulated market. Addition the connection fails to load because I'm pretty lost with tech as someone from generation x so try searching the title discussing the continued debate on testing plus the writer's name.

Add your experience

If you have tried it, this topic is still open. Sign in to reply — it takes a minute.